Business Wire

CA-VERIMATRIX

9.11.2020 17:47:11 CET | Business Wire | Press release

Share
Verimatrix Launches New Brand Campaign: Security Made for People

Regulatory News:

Verimatrix , (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced its new brand campaign, "Security Made For People," along with a revamped website and supporting brand identity elements.

Designed to authentically capture the human side of security, the campaign provides a glimpse into the real challenges facing Verimatrix customers and technology partners as they work hard to secure their digital content and applications in an increasingly hostile cyber world. The campaign highlights success stories spanning a wide range of industries such as media and entertainment, finance and live sports.

Verimatrix's "Security Made for People" campaign features a branded unveiling that includes short-form videos running across digital channels, social media stories, and a fully redesigned website. Website visitors can experience enriched storytelling content that shines a light on the business issues Verimatrix addresses, solutions deployed, and benefits gained. Completely re-written and reimagined, the new Verimatrix website has also extended the breadth and depth of its content, highlighting new markets such as live streaming sports and eSports. Post-launch, the website will roll out additional solutions, a new investor section, and multi-language support in Spanish, French, Japanese and Mandarin.

The company’s brand identity detail, from its imagery to color choice, reflects Verimatrix’s brand essence of integrity. For example, the new color palette energizes existing core brand colors and further enhances the overall visual impact with a boost of saturation and vibrancy. Other shifts include the addition of new fonts and lifestyle photography, creating a more emotional connection with prospective customers, reseller partners and their end users.

“Verimatrix has gone through some exciting changes recently and our new brand positioning reflects the maturity and sophistication of the company,” said Jon Samsel , Vice President of Global Marketing at Verimatrix. "The Verimatrix brand is built around the idea of people-centered and frictionless security. It highlights how we empower our customers and technology partners with the ability to integrate, deploy and monetize professional-grade security solutions that are friendly and easy to use.”

People-centered means putting customers, business partners and their end users first. It’s about active listening, sharing more than selling, and tailoring products, solutions and experiences for the people Verimatrix serves. For 25 years Verimatrix has been consistently recognized for its ability to empower organizations to safeguard valuable content, applications and devices at scale, on premises or in the cloud, while maximizing revenue.

“Frictionless security is akin to friendly security – and this isn't an oxymoron; it’s about making the security experience as simple and transparent as possible,” said Asaf Ashkenazi , Chief Operating Officer at Verimatrix. “Friendly security is that magic place between robustness and ease of use. In fact, good security that is easy to deploy and largely invisible to the end user is far more effective than great security that goes unused. We’re excited that our new website and ad campaign are able to highlight our ‘experience first’ approach to engineering.”

Visit www.verimatrix.com to experience the company’s brand evolution and new Security Made for People campaign.

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com .

Social Media:

https://www.facebook.com/VerimatrixInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye